With Pfizer, AZ and Merck leading the way, Big Pharma weathered the economic storm in Q2

With Pfizer, AZ and Merck leading the way, Big Pharma weathered the economic storm in Q2

Source: 
Fierce Pharma
snippet: 

Inflation. Supply chain issues. The Ukraine war. Rising interest rates. Pandemic lockdowns in China.

Put them all together and you’ve got increased volatility and economic uncertainty that hindered many business sectors worldwide in the second quarter. But a look at the sales performance of top drugmakers shows that the biopharma industry is largely navigating those challenges.

Of two dozen top companies in the sector (see graph), 15 increased their revenue from the same quarter of 2021. More than half delivered sequential revenue increases from the first quarter of this year.